Oxford Pharmascience makes statin breakthrough
Specialty pharmaceutical Oxford Pharmascience (OXP:AIM) jumped 6% to 2.85p after saying it is ready to make products for use later this year in proof of concept clinical trials under its Safestat programme. The news expands the...
28 January 2013